MP4•Episode home
Manage episode 491318606 series 2740117
Content provided by MasterMedFacts LLC and RR Baliga MD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC and RR Baliga MD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
🚨 New Breakthrough in Type 2 Diabetes Care! 💊🧬
The ACHIEVE-1 trial shows that Orforglipron, a once-daily oral, nonpeptide GLP-1 receptor agonist, delivers significant reductions in HbA1c and body weight—without injections and with minimal restrictions! 🌍📉
👨⚕️ 559 patients across 5 countries
⏱️ 40 weeks, 3 dosing arms (3, 12, 36 mg)
📊 HbA1c ↓ by up to 1.48%, weight ↓ up to 7.6%
✅ No severe hypoglycemia
📌 Mild GI side effects during dose titration
This is a potential gamechanger for early T2DM care—simple, effective, and patient-friendly. 🚀
#Type2Diabetes #GLP1 #Orforglipron #Endocrinology #ClinicalTrials #PrecisionMedicine #Innovation #NEJM #ACHIEVE1 #OralTherapeutics 💥
549 episodes